Image de couverture de livre

Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Shen Cheng, Mahmoud Al‐Kofahi, J. Steven Leeder, Jacob T. Brown
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Correction to “Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit/Hyperactivity Disorder”
Publié: (2025)

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement
par: Abdelrahman Saqr, et autres
Publié: (2025)

Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics
par: Kevin. V. Tobin, et autres
Publié: (2026)

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis
par: Jenny‐Hoa Nguyen, et autres
Publié: (2026)

Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults
par: Jaime Algorta, et autres
Publié: (2024)

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children
par: Sylvie Retout, et autres
Publié: (2026)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
par: Benjamin Rich, et autres
Publié: (2025)

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents
par: Ethan A. Poweleit, et autres
Publié: (2024)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
par: Weihua Jiang, et autres
Publié: (2025)

Piperacillin Population Pharmacokinetics in Plasma and Peritoneal Fluid and Dosing Optimization in Children Undergoing Liver Transplant: An Optimome Study
par: Noémie de Cacqueray, et autres
Publié: (2026)

Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
par: Aarzoo Thakur, et autres
Publié: (2024)

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
par: Ziheng Hu, et autres
Publié: (2026)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
par: Xiaoyu Men, et autres
Publié: (2024)

Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model
par: Thomas K. Henthorn, et autres
Publié: (2025)

Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
par: Md Masud Parvez, et autres
Publié: (2024)

Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure‐Response Analysis
par: Xiaofei Zhou, et autres
Publié: (2025)

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
par: Jincheng Yang, et autres
Publié: (2025)

Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling
par: Suwasin Udomkarnjananun, et autres
Publié: (2024)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
par: Peiying Zuo, et autres
Publié: (2024)

Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
par: Tetsuro Ogawa, et autres
Publié: (2025)

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity
par: Patrick O. Hanafin, et autres
Publié: (2025)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
par: Aiden‐Hung P. Nguyen, et autres
Publié: (2026)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
par: Lukas K. van Vugt, et autres
Publié: (2025)

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
par: Neha Thakre, et autres
Publié: (2024)

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy
par: Emiel Leegwater, et autres
Publié: (2024)

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth
par: Jack W. Staples, et autres
Publié: (2026)

Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV
par: Paul Thoueille, et autres
Publié: (2024)

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations
par: Kaio Evandro Cardoso Aguiar, et autres
Publié: (2026)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
par: Jatinder Kaur Mukker, et autres
Publié: (2025)

A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition
par: Stef Schouwenburg, et autres
Publié: (2024)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
par: Gerald Chun‐To So, et autres
Publié: (2025)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
par: Kenichi Umehara, et autres
Publié: (2024)

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
par: Yuki Ujihira, et autres
Publié: (2025)

Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
par: Olena Anoshchenko, et autres
Publié: (2024)

Comment on “Understanding Atomoxetine Exposure Variability in Children and Adolescents with ADHD through Population Pharmacokinetics”
par: Madhuri Tribhuvan, et autres
Publié: (2026)

Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
par: Javiera Cortés‐Ríos, et autres
Publié: (2025)

A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus
par: Gerald C. So, et autres
Publié: (2024)

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
par: Emily Mannix, et autres
Publié: (2026)

Best Practices for Pharmacokinetic Studies of New Chemical Entities
par: Ya‐Feng Wen, et autres
Publié: (2024)

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients
par: Eleanor A. Lisbon, et autres
Publié: (2025)